To appraise the clinical and cost effectiveness of Tislelizumab within its marketing authorisation for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy.
- Status:
- Awaiting development
- Technology type:
- Medicine
- Decision:
- Selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS
- Process:
- Cost Comparison Standard
- ID number:
- 6682
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email TACommB@nice.org.uk
Stakeholders
- Companies sponsors
- BeOne
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Barrett’s UK
- Black Health Agency for Equality
- Cancer 52
- Cancer Black Care
- Cancer Equality
- GIST Cancer UK
- GUTS UK
- Heartburn Cancer UK
- Independent Cancer Patients Voice
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie
- Ochre
- Oesophageal Patients Association
- OG Support formerly Together Support Group
- Oracle Head and Neck Cancer UK
- OOSO (Oxford Oesophageal and Stomach Organisation)
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus Cancer Care
- Professional groups
- Association of Anaesthetists of Great Britain and Ireland
- Association of Cancer Physicians
- Association of Surgeons of Great Britain and Ireland
- Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland
- British Association of Surgical Oncology
- British Geriatrics Society
- British Institute of Radiology
- British Oncology Pharmacy Association
- British Psychosocial Oncology Society
- British Society of Gastroenterology
- Cancer Research UK
- Primary Care Society for Gastroenterology
- Royal College of Anaesthetists
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal College of Surgeons
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Clinical Pharmacy Association
- UK Oncology Nursing Society
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Bristol Myers Squibb Pharmaceuticals (nivolumab)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Welsh Health Specialised Services Committee
- Relevant research groups
- Genomics England
- Institute of Cancer Research
- MRC Clinical Trials Unit
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 17 March 2026 | Invitation to participate |
| 16 February 2026 - 03 March 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 21 February 2026 | Awaiting development. Status change linked to topic prioritisation decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual